ClinicalTrials.gg

TargetBeta

KMT2A

lysine methyltransferase 2A · also TRX1, HRX, ALL-1, HTRX1 · PHD finger proteins

4 programs in company-led studies act on KMT2A, from 4 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
ziftomenibruleKura Oncologyphase 366 running–NCIt
revumenibruleSyndax Pharmaceuticalsphase 364 runningMEN1NCIt
bleximenibJohnson & Johnsonphase 342 runningMEN1a judged reading
icovamenibruleBiomea Fusionphase 272 running–NCIt

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.